[196] Lower starting doses are typically recommended for elderly patients, with more gradual dose escalation and careful monitoring for adverse effects
SURPASS-2 results (40 weeks, type 2 diabetes): Tirzepatide 5 mg: -7.6 kg weight loss, -2.01% HbA1c reduction Tirzepatide 10 mg: -9.3 kg weight loss, -2.24% HbA1c reduction Tirzepatide 15 mg: -11.2 kg weight loss, -2.30% HbA1c reduction Semaglutide 1 mg: -5.7 kg weight loss, -1.86% HbA1c reduction SURMOUNT-5 results (72 weeks, obesity): Tirzepatide demonstrated statistically superior weight loss compared to semaglutide 2.4 mg
Tesamorelin is studied specifically for visceral fat reduction in HIV patients, with documented efficacy
A yellow or brownish tint is a sign that the medication has oxidized or the proteins have broken down
Some retatrutide users report awareness of their heartbeat, particularly during the dose-escalation phase
Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus